'Tobacco-free claims in tobacco product marketing in the United States
Tobacco control research, policy and advocacy are replete with ‘tobacco-free’ terminology. For instance, there are tobacco-free initiatives targeting removal of tobacco use, imagery and branding from major entertainment media.1 2 There are also policies promoting tobacco-free college campuses,3 parks,4 pharmacies5 and workplaces6 which help protect the environment from tobacco product litter, reduce exposure to secondhand smoke and denormalise tobacco use. The goals of these and other efforts are to create a tobacco-free generation7 and even a tobacco-free world.8 In recent years, tobacco manufacturers have beg...
Source: Tobacco Control - April 19, 2024 Category: Respiratory Medicine Authors: Seidenberg, A., Kaufman, A. Tags: Special communication Source Type: research
Promoting new users ’ online health consultation services usage behavior strategically
. (Source: Health Marketing Quarterly)
Source: Health Marketing Quarterly - April 18, 2024 Category: International Medicine & Public Health Authors: Annie ChenWei-Min ChuNorman Penga Roehampton Business School, Roehampton University, London, United Kingdomb Division Chief of Family Medicine, Taichung Veterans General Hospital, Taichung, Taiwanc National Yang Ming Chiao Tung University, Hsinchu, Taiwan Source Type: research
Decolonizing Impact Through the Culture-Centered Approach to Health Communication: Mobilizing Communities to Transform the Structural Determinants of Health
. (Source: Health Communication)
Source: Health Communication - April 18, 2024 Category: Health Management Authors: Mohan J. DuttaSatveer Kaur-GillSelina Metuamatea Center for Culture-Centered Approach to Research and Evaluation (CARE), School of Communication, Journalism and Marketing, Massey Universityb Department of Communication Studies, University of Nebraska-Linc Source Type: research
Current uncertainties and challenges of publicly available pharmaceutical environmental risk assessment data
Eur J Pharm Sci. 2024 Apr 16;197:106769. doi: 10.1016/j.ejps.2024.106769. Online ahead of print.ABSTRACTPharmaceutical residues are widely detected in aquatic environment worldwide mainly arising from human excretions in sewage systems. Presently, publicly available, high quality environmental risk assessment (ERA) data for pharmaceuticals are limited. However, databases like the Swedish Fass offer valuable resources aiding healthcare professionals and environmental scientists in identifying substances of significant concern. In this review, we provide a concise overview of the regulatory ERA process for medicinal products...
Source: European Journal of Pharmaceutical Sciences - April 17, 2024 Category: Drugs & Pharmacology Authors: H Ahkola L Äystö T Sikanen S Riikonen T Pihlaja S Kauppi Source Type: research
Current uncertainties and challenges of publicly available pharmaceutical environmental risk assessment data
Eur J Pharm Sci. 2024 Apr 15:106769. doi: 10.1016/j.ejps.2024.106769. Online ahead of print.ABSTRACTPharmaceutical residues are widely detected in aquatic environment worldwide mainly arising from human excretions in sewage systems. Presently, publicly available, high quality environmental risk assessment (ERA) data for pharmaceuticals are limited. However, databases like the Swedish Fass offer valuable resources aiding healthcare professionals and environmental scientists in identifying substances of significant concern. In this review, we provide a concise overview of the regulatory ERA process for medicinal products int...
Source: European Journal of Pharmaceutical Sciences - April 17, 2024 Category: Drugs & Pharmacology Authors: H Ahkola L Äystö T Sikanen S Riikonen T Pihlaja S Kauppi Source Type: research
Unhealthy Food and Beverage Marketing to Children in the Digital Age: Global Research and Policy Challenges and Priorities
Annu Rev Nutr. 2024 Apr 17. doi: 10.1146/annurev-nutr-062322-014102. Online ahead of print.ABSTRACTFood and nonalcoholic beverage marketing is implicated in poor diet and obesity in children. The rapid growth and proliferation of digital marketing has resulted in dramatic changes to advertising practices and children's exposure. The constantly evolving and data-driven nature of digital food marketing presents substantial challenges for researchers seeking to quantify the impact on children and for policymakers tasked with designing and implementing restrictive policies. We outline the latest evidence on children's experien...
Source: Annual Review of Nutrition - April 17, 2024 Category: Nutrition Authors: Emma Boyland Kathryn Backholer Monique Potvin Kent Marie A Bragg Fiona Sing Tilakavati Karupaiah Bridget Kelly Source Type: research
Unhealthy Food and Beverage Marketing to Children in the Digital Age: Global Research and Policy Challenges and Priorities
Annu Rev Nutr. 2024 Apr 17. doi: 10.1146/annurev-nutr-062322-014102. Online ahead of print.ABSTRACTFood and nonalcoholic beverage marketing is implicated in poor diet and obesity in children. The rapid growth and proliferation of digital marketing has resulted in dramatic changes to advertising practices and children's exposure. The constantly evolving and data-driven nature of digital food marketing presents substantial challenges for researchers seeking to quantify the impact on children and for policymakers tasked with designing and implementing restrictive policies. We outline the latest evidence on children's experien...
Source: Annual Review of Nutrition - April 17, 2024 Category: Nutrition Authors: Emma Boyland Kathryn Backholer Monique Potvin Kent Marie A Bragg Fiona Sing Tilakavati Karupaiah Bridget Kelly Source Type: research
Increased risk of hypocalcemia with decreased kidney function in patients prescribed bisphosphonates based on real-world data from the MID-NET ® in Japan: a new-user cohort study
In the post-marketing stage, cases of hypocalcemia associated with bisphosphonate preparations (BPs) have been reported in patients with decreased kidney function, despite warning against use of BPs in such pa... (Source: BMC Nephrology)
Source: BMC Nephrology - April 15, 2024 Category: Urology & Nephrology Authors: Tomoaki Hasegawa, Maki Komamine, Chieko Ishiguro, Haruka Motomura, Kazuhiro Kajiyama, Takahiro Nonaka, Yuki Nakazato, Ryota Kimura, Harumi Maniwa, Toyotaka Iguchi, Naoya Horiuchi and Yoshiaki Uyama Tags: Research Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
Adjusting starting points for initial price offers: the example of ibrutinib
This article focuses on the data obtained for ibrutinib, an oral medication for treating hematologic malignancies, which is one of the only drugs reviewed by the committee that also has been selected for Medicare price negotiation. We examine data that can be obtained only from the drug manufacturer that the IRA has explicitly identified as being used to determine the price and suggest potential negotiation strategies for CMS in response.PMID:38603534 | DOI:10.37765/ajmc.2024.89531 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - April 11, 2024 Category: Health Management Authors: Jason B Gibbons Charles L Bennett Kenneth R Carson Gerard F Anderson Source Type: research
